Advisors Asset Management Inc. Lowers Stock Holdings in Stryker Corporation $SYK

Advisors Asset Management Inc. cut its holdings in shares of Stryker Corporation (NYSE:SYK) by 0.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,447 shares of the medical technology company’s stock after selling 174 shares during the quarter. Advisors Asset Management Inc.’s holdings in Stryker were worth $12,046,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Columbia Bank grew its position in shares of Stryker by 3.0% during the second quarter. Columbia Bank now owns 5,987 shares of the medical technology company’s stock worth $2,332,000 after purchasing an additional 177 shares in the last quarter. Laurel Wealth Advisors LLC boosted its stake in Stryker by 39,309.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 59,902 shares of the medical technology company’s stock worth $23,699,000 after purchasing an additional 59,750 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in Stryker by 23.5% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 32,863 shares of the medical technology company’s stock worth $13,002,000 after purchasing an additional 6,264 shares during the period. Quadcap Wealth Management LLC grew its holdings in Stryker by 1.1% during the 2nd quarter. Quadcap Wealth Management LLC now owns 3,514 shares of the medical technology company’s stock valued at $1,390,000 after buying an additional 38 shares in the last quarter. Finally, Insigneo Advisory Services LLC raised its position in shares of Stryker by 35.3% during the second quarter. Insigneo Advisory Services LLC now owns 1,220 shares of the medical technology company’s stock valued at $483,000 after buying an additional 318 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. BTIG Research restated a “buy” rating and set a $410.00 target price on shares of Stryker in a research report on Friday, November 14th. Evercore ISI dropped their price objective on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Rothschild & Co Redburn started coverage on Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a report on Wednesday, November 19th. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $434.37.

Stryker Price Performance

Stryker stock opened at $370.38 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market cap of $141.64 billion, a price-to-earnings ratio of 49.06, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The firm has a 50-day moving average of $369.24 and a two-hundred day moving average of $380.59. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Insider Activity

In related news, CAO William E. Berry, Jr. sold 1,953 shares of Stryker stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the sale, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 522,118 shares of company stock worth $185,381,932. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.